Recent news on Velcade

Doxil® Approved for Multiple Myeloma in Conjunction with Velcade®  -  25 May 2007
Cancer Consultants (press release),The US Food and Drug Administration (FDA) announced on May 17, 2007 the approval of Doxil (liposomal doxorubicin) plus Velcade for the treatment of patients

Bank of America 2007 Healthcare Conference to Webcast Millennium ...  -  25 May 2007
PharmaLive.com (press release),Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection,

Velcade Plus Doxil Approved For Myeloma Treatment  -  May 22, 2007
eMaxHealth.com,The combination of Doxil with Velcade provides nearly a three month improvement in time to disease progression as compared to Velcade alone, which is a 43%

The International Myeloma Foundation Reports New Drug Combination ...  -  May 22, 2007
Medical News Today (press release),The combination of Doxil(R) with Velcade(R) provides nearly a three month improvement in time to disease progression as compared to Velcade alone,

Doxil/Velcade Combination Therapy Approved for Myeloma  -  May 22, 2007
Facts and Comparisons,The FDA has approved a new combination treatment, Doxil (doxorubicin liposomal) with Velcade (bortezomib), for myeloma in patients who have relapsed or have

Hard-up NHS cuts back on homoeopathy  -  May 22, 2007
Times Online,The NHS should not be funding such therapies while it had to refuse or ration access to effective cancer drugs such as Herceptin and Velcade,

UPDATE 2-US FDA clears J&J, Millennium cancer drug combo  -  May 18, 2007
ReutersThe Food and Drug Administration said it cleared use of J&J's drug Doxil with Millennium's Velcade in patients with multiple myeloma who have not received

UPDATE 2-Millennium Pharmaceuticals 1st-qtr loss narrows  -  Apr 26, 2007
ReutersO: Quote, Profile , Research) said on Thursday quarterly loss narrowed, helped by sales of cancer drug Velcade, royalties and a decrease in stock-based

Gemin X Biotechnologies Announces Publication in Blood of Positive ...  -  May 15, 2007
PharmaLive.com (press release),Additionally, the compound synergized with bortezomib (Velcade(R)), a proteasome inhibitor, such that MCL cells became sensitized to low doses of bortezomib

Kosan Announces First Quarter 2007 Financial Results; Plans to ...  -  May 10, 2007
PharmaLive.com (press release),Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc. Herceptin(R) (trastuzumab) is a registered trademark of Genentech,

Beacon Capital completes sale of buildings for $4.8b  -  May 18, 2007
Boston Globe,Johnson & Johnson said US regulators approved combining its Doxil shot with Millennium Pharmaceuticals Inc.'s Velcade to treat cancer of plasma cells.

Citigroup 2007 Healthcare Conference to Webcast Millennium ...  -  May 18, 2007
PharmaLive.com (press release),Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection,

Citigroup 2007 Healthcare Conference to Webcast Millennium ...  -  May 17, 2007
PR Newswire (press release),About Millennium Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for

Gemin X Biotechnologies Announces Publication in Blood of Positive ...  -  May 15, 2007
Business Wire (press release),Additionally, the compound synergized with bortezomib (Velcade®), a proteasome inhibitor, such that MCL cells became sensitized to low doses of bortezomib.

The drugs the NHS won't give you  -  May 10, 2007
Telegraph.co.uk,Mr King, who is terminally ill with bone marrow cancer was forced to consider moving to Scotland to get access to Velcade in an attempt to prolong his life.

Human Genome Sciences Announces First Quarter 2007 Financial ...  -  May 9, 2007
PR Newswire (press release),A separate poster presentation reported the results of a preclinical study, which demonstrated that low concentrations of Velcade (bortezomib) can be used

Millennium Reports Strong Financial and Operational Results for ...  -  26 Apr 2007
PharmaLive.com (press release),..."Financially, we delivered strong first-quarter results which reflect both global VELCADE revenue growth and continued expense management," commented Marsha

Millenium trims losses in Q1  -  26 Apr 2007
MSN MoneyMillennium attributed the improved numbers, in part, to increased sales of Velcade, its treatment for the blood cancer multiple myeloma.

CuraGen Reports First Quarter 2007 Financial Results and Updated ...  -  26 Apr 2007
Earthtimes.orgHI; -- Preliminary Phase II results of intravenous belinostat in combination with Velcade(R) (bortezomib) for Injection for advanced relapsed/refractory

Controversial NHS 'top up' scheme is launched  -  Apr 25, 2007
Daily Mail,Ten drugs so far are on the list, including Avastin for bowel cancer, Alimta for lung cancer, kidney cancer drugs Nexavar and Sutent, and Velcade for

Millennium Discovers Biomarkers Potentially Predictive Of Response ...  -  Apr 18, 2007
Medical News Today (press release),VELCADE is the US market leading therapy for previously treated multiple myeloma patients with an unsurpassed median survival of 29.8 months as a single

Preventing protein recycling to tackle leukaemia  -  Apr 23, 2007
DrugResearcher.com,Millennium Pharmaceuticals' Velcade (bortezomib) is the first and only proteasome inhibitor drug approved by the US Food and Drug Administration (FDA) - in

NICE Appeal Ruling On Velcade Signals Positive Step Forward, UK  -  Mar 29, 2007
Medical News Today (press release),The NICE Appeals Panel ruled that as Velcade is the first in a new class of treatment then, "if it [NICE] should decline to recommend bortezomib [Velcade]

NICE applauded for choosing to rethink Velcade review  -  Mar 30, 2007
Pharma Times (subscription),Velcade (bortezomib), which treats myeloma, a form of bone marrow cancer, had been rejected by NICE on the grounds of cost but the agency would appear to

Velcade®, Alkeran®, Prednisone, and Thalomid® Effecive for ...  -  Mar 28, 2007
Cancer Consultants (press release),...conducted a clinical trial to evaluate VMPT (Velcade, Alkeran, Thalomid, and prednisone) in the treatment of 30 patients with relapsed multiple myeloma.

AMID WARD'S ANTIQUATED CONDITIONS, DAD'S CANCER CARE WAS SECOND TO ...  -  Apr 21, 2007
this is staffordshire,His consultant even won a battle with local NHS funders to secure him doses of a medication called Velcade, which had not been approved by Government

Bortezomib Boosts Response When Myeloma Comes Back  -  Apr 20, 2007
Cancerpage.com,Dr. Palumbo of the University of Turin and colleagues came to this conclusion after studying the effect of the MPT+ bortezomib (Velcade) combination (VMPT)

Millennium to Webcast First-Quarter 2007 Financial Results  -  Apr 20, 2007
PharmaLive.com (press release),Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection,

New Life-extending Drugs Drive Revenues in the US Multiple Myeloma ...  -  Apr 17, 2007
Newswire Today (press release),Particularly at the forefront of modern day multiple myeloma therapy are Thalomid, Revlimid, and Velcade—all fostering an unprecedented growth in the US

Zeltia presents positive drug test results to US cancer research group  -  Apr 19, 2007
Forbes,In a statement, the group said tests on Aplidin in combination with Velcade had produced 'encouraging results' while Zalypsis had shown 'a significant

Hope for cancer victims as drug ban is overruled  -  Mar 28, 2007
Daily Mail,The ruling that Velcade should not be prescribed on the Health Service to bone cancer victims in England caused outrage last year because it is available in

Ruling provides hope for cancer patients  -  Mar 29, 2007
The Northern Echo,Until recently, Redcar and Cleveland Primary Care Trust (PCT) was refusing to pay for Mr King to be treated with a new drug called Velcade, which can extend

Charities hail drug ruling review  -  Mar 29, 2007
Channel 4 News,Chiefs on the Nice appeals panel have now ruled that as Velcade is the first in a new class of treatment, the Nice committee must fully explain its reasons

'Wonder drug kept me alive'  -  Apr 7, 2007
Oxford Mail,However, at the 11th hour his doctor informed him of a trial for the drug - called Velcade at the Royal Marsden Hospital in London.

Review on vital cancer drug  -  Apr 2, 2007
Norwich Evening News,The National Institute for Clinical Excellence (NICE) took Velcade off NHS shelves last year which is used to treat the incurable bone marrow cancer myeloma

Analysis: Street mixed on Celgene's drug  -  Apr 5, 2007
United Press InternationalMillennium's Velcade, a competitor to Revlimid, had a marginally lower reduction in survival in a similarly designed study. However, Osborne said he assumes

Kosan Biosciences to Present at the CIBC World Markets Annual ...  -  Apr 5, 2007
PharmaLive.com (press release),NOTE: Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc. Herceptin(R) (trastuzumab) is a registered trademark of

Petitioners win cancer drug pledge  -  Apr 5, 2007
ic Coventry,Styvechale, have been helping the charity Myeloma UK to collect up to a million signatures to make the drug Velcade available on prescription.

TopoTarget and CuraGen Initiate Phase II Trial of Belinostat ...  -  Apr 2, 2007
Oxfordshire Bioscience Network (press release),...in combination with Velcade® (bortezomib) for Injection, in multiple myeloma patients refractory to or who have rapidly relapsed from at least one

CuraGen Shares Drop on Deal  -  Mar 29, 2007
Houston Chronicle,The start of a second midstage study, however, for its belinostat in combination with Velcade to treat refractory multiple myleoma will likely be delayed by

Market highlights for next week: Alcoa reporting -- Another ...  -  Apr 5, 2007
Blogging StocksPDUFA Date for Millennium Pharmaceuticals Inc's (NASDAQ: MLNM) Velcade, which is a new type of cancer drug called a proteasome inhibitor.

Appeal on Cancer Drug  -  Mar 30, 2007
FemaleFirst.co.uk,The National Institute for Health and Clinical Excellence disclosed that bone marrow cancer medication Velcade is not "cost-effective" at £18000 a year per

CuraGen and TopoTarget Initiate Phase II Trial of Belinostat ...  -  Mar 27, 2007
PipelineReview.com (press release),...in combination with Velcade(R) (bortezomib) for Injection, in multiple myeloma patients refractory to or who have rapidly relapsed from at least one

The Multiple Myeloma Research Consortium And Nereus ...  -  Apr 17, 2007
Medical News Today (press release),The compound is a potent inhibitor of human proteasomes, a high- interest drug target for pharmaceutical companies after Velcade(R) (bortezomib,

Kosan Presents Data On Cardiac Safety Profile Of Hsp90 Inhibitor ...  -  Apr 17, 2007
Medical News Today (press release),Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc. Herceptin(R) (trastuzumab) is a registered trademark of Genentech,

Cancer Drugs A Key In MedImmune Purchase  -  Apr 23, 2007
Forbes,Infinity's chief scientist, chemist Julian Adams, also invented Velcade, from Millennium Pharmaceuticals (nasdaq: MLNM - news - people ).

New Life-extending Drugs Drive Revenues in the US Multiple Myeloma ...  -  Apr 16, 2007
PR Newswire (press release),Particularly at the forefront of modern day multiple myeloma therapy are Thalomid, Revlimid, and Velcade -- all fostering an unprecedented growth in the US

Analysis: Surge forecast for Pharmion drug  -  Mar 30, 2007
Science Daily (press release)..."Thalidomide will probably be about one-quarter the cost of Velcade and Revlimid regimens," Bouchey said, noting that cost is a significant advantage under

CuraGen and TopoTarget Announce New Clinical Results With ...  -  Apr 19, 2007
PharmaLive.com (press release),...with other active anti-cancer agents, including 5-FU, carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade(R) (bortezomib) for Injection.

Kosan Presents Preclinical Data on Nuclear Export Inhibitors ...  -  Apr 18, 2007
PR Newswire (press release),...primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R)

TopoTarget Announces New Preclinical Results with Belinostat to be ...  -  Apr 13, 2007
Oxfordshire Bioscience Network (press release),...with other active anti-cancer agents, including 5-FU, carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade® (bortezomib) for Injection.

Synta Pharmaceuticals Corp. Strengthens Oncology Clinical and ...  -  Apr 12, 2007
PharmaLive.com (press release),...roles for each of VELCADE's three indication launches (3rd line multiple myeloma, 2nd line multiple myeloma, and 2nd line mantle cell lymphoma).

Synta Pharmaceuticals Corp. Strengthens Oncology Clinical and ...  -  Apr 12, 2007
Business Wire (press release),...roles for each of VELCADE’s three indication launches (3 rd line multiple myeloma, 2 nd line multiple myeloma, and 2 nd line mantle cell lymphoma).

TopoTarget of Denmark buys Swiss biotech firm Apoxis for 14.5 ...  -  Apr 12, 2007
Pharma Times (subscription),...or in combination with other active anti-cancer agents, including 5-FU, carboplatin, paclitaxel and Millennium Pharmaceuticals' Velcade (bortezomib).

CIBC World Markets Annual Biotechnology & Specialty ...  -  Apr 6, 2007
PR Newswire (press release),About Millennium Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for

CuraGen and TopoTarget Initiate Phase II Trial of Belinostat ...  -  27 Mar 2007
Earthtimes.org...in combination with Velcade(R) (bortezomib) for Injection, in multiple myeloma patients refractory to or who have rapidly relapsed from at least one

Velcade®, Alkeran®, Prednisone and Thalomid® Effecive for Relapsed ...  -  Mar 23, 2007
Cancer Consultants (press release),Velcade 1.0 to 1.3 mg/m2 was given on days 1, 4, 15 and 22. Alkeran was given at a dose of 6 mg/m2 on days 1-5 and prednisone 60 mg.m2 on days 1-5.

Pharmacy: Cancer care can leave bankrupt  -  Mar 25, 2007
Houston Chronicle,Someone with myeloma could survive many years thanks to Revlimid and Velcade. A family without insurance could end up with a bill in the hundreds of

Velcade® Safe and Effective for Patients with Multiple Myeloma and ...  -  Mar 14, 2007
Cancer Consultants (press release),Velcade is considered a proteosome inhibitor. Proteosomes are proteins found in virtually all cells. They are responsible for the breakdown and reuse of a

Kosan Biosciences to Present at the Future Leaders in the Biotech ...  -  Mar 23, 2007
PharmaLive.com (press release),NOTE: Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc. Herceptin(R) (trastuzumab) is a registered trademark of

Researchers Wake Up Viruses Inside Tumors to Image and Then ...  -  Mar 8, 2007
WebWire (press release),The researchers screened 2700 agents until they hit upon Velcade, a targeted chemotherapy drug already approved for use in multiple myeloma.

Activating Epstein-Barr Virus Helps Imaging of Certain Cancers  -  Mar 1, 2007
Genetic Engineering News (press release),Regarding the use of Velcade, Dr. Pomper explains that it “is a proteasome inhibitor, but it also induces the lytic cycle thereby activating the TK in the

Lehman Brothers Tenth Annual Global Healthcare Conference To ...  -  Mar 13, 2007
PharmaLive.com (press release),Millennium management will provide an overview of the Company, its marketed product VELCADE(R) (bortezomib) for Injection and its pipeline.

New Clinical Data for Cytogen’s QUADRAMET and PROSTASCINT to be ...  -  Mar 26, 2007
Business Wire (press release),Additionally, new and complete data from a Phase 1 study evaluating QUADRAMET in combination with bortezomib (Velcade®, Millennium Pharmaceuticals,

Kosan Announces Fourth Quarter and Full-Year 2006 Financial ...  -  Feb 27, 2007
PR Newswire (press release),TIME-1, a Phase 3 trial, will test tanespimcin plus Velcade(R) compared to Velcade alone in a first-relapsed setting. TIME-2, a Phase 2/3 companion trial,

Lehman Brothers Tenth Annual Global Healthcare Conference To ...  -  Mar 12, 2007
PR Newswire (press release),About Millennium Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for

Tumor-causing virus used to kill tumors  -  Mar 1, 2007
United Press InternationalIf the tumor glows, indicating that virus is present, they administer a chemotherapy drug called Velcade, which is used to treat the bone marrow malignancy

Successful Islet Cell Transplant in Mice With Type 1 Diabetes  -  Mar 10, 2007
MedIndia,The proteasome inhibitor bortezomib (Velcade®) causes this jamming process and restores p53 function. However, if p53 was inactivated in the mice,

Cancer drug may turn immune system against tumors  -  Feb 26, 2007
Asbury Park Press,Researchers from Rockefeller University say that the cancer drug bortezomib, also known as Velcade has the potential to enhance cancer patients' immunity to

The International Myeloma Foundation Says Recommendation For ...  -  Mar 24, 2007
Medical News Today (press release),When approved it will join the other novel therapies including Thalomid (thalidomide) also from Celgene and distributed by Pharmion in Europe, and Velcade

Kosan Biosciences to Present at the Future Leaders in the Biotech ...  -  Mar 22, 2007
PR Newswire (press release),...primarily for multiple myeloma in combination with Velcade(R) and HER2-positive metastatic breast cancer in combination with Herceptin(R).

Vidacare names new head of hematology/oncology  -  Mar 22, 2007
Milwaukee Business Journal,She is a former oncology specialist at Millennium Pharmaceuticals, where she launched Velcade, a proteasome inhibitor, in the oncology market.

Roche And Kosan To Initiate Phase 2 Cancer Development Program ...  -  Feb 28, 2007
Medical News Today (press release),Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc. Herceptin(R) (trastuzumab) is a registered trademark of Genentech,

Vidacare ® Announces Sales and Marketing Leader for New Hematology ...  -  Mar 20, 2007
Business Wire (press release),During her tenure there, she successfully launched Velcade, a first-in-class proteasome inhibitor, to the oncology market. Ms. Ariana previously served as

Business notebook  -  Mar 14, 2007
Boston Globe,3 more years: Millennium Pharmaceuticals Inc. won an extension of its US patent covering the multiple myeloma drug Velcade for injection.

Cowen and Company 27th Annual Health Care Conference to Webcast ...  -  Mar 8, 2007
PharmaLive.com (press release),Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection,

From the analyst's couch: Multiple myeloma therapies  -  Mar 2, 2007
Nature.com (subscription),In 2003, bortezomib (Velcade; Millenium) became the first drug approved by the US FDA for use in patients with relapsed or refractory MM.

Cancer May Lose Battle With Viruses  -  Mar 1, 2007
KPTV.com,..."Velcade is only one of an array of new, as well as older agents, that can induce lytic infection, and a particular agent could be tailored for use in a

Cytogen Reports Fourth Quarter and Full Year 2006 Financial Results  -  Mar 1, 2007
PharmaLive.com (press release),...sanofi-aventis) for the treatment of hormone-refractory prostate cancer and a Phase 2 study evaluating QUADRAMET and bortezomib (Velcade(R),

Cytogen Reports Fourth Quarter and Full Year 2006 Financial Results  -  Feb 28, 2007
Business Wire (press release),...cancer and a Phase 2 study evaluating QUADRAMET and bortezomib (Velcade ® , Millenium Pharmaceuticals, Inc.) for the treatment of multiple myeloma.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional